Ann Arbor, MI, United States of America

John S Kiely


Average Co-Inventor Count = 3.6

ph-index = 21

Forward Citations = 1,566(Granted Patents)

Forward Citations (Not Self Cited) = 1,553(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Ann Arbor, MI (US) (1986 - 1998)
  • San Diego, CA (US) (1996 - 2007)

Company Filing History:


Years Active: 1986-2007

Loading Chart...
Areas of Expertise:
Peptide Nucleic Acids
Nuclear Receptor Binding Compounds
Amyloid Protein Aggregation
Mitochondrial Targeting
Isoquinoline Compounds
Quinoline Derivatives
Combinatorial Libraries
Antibacterial Agents
Chemical Synthesis Apparatus
Tricyclic Tetrahydroquinoline
Pharmaceutical Compositions
Stereoisomers
58 patents (USPTO):Explore Patents

Title: Revolutionizing Home Automation: A Smart System Powered by John S Kiely's Patents

Introduction:

In today's fast-paced digital age, the concept of a smart home has garnered immense popularity. People are increasingly looking for innovative ways to enhance their living spaces by seamlessly integrating various devices and appliances. Addressing this ever-growing demand, John S Kiely, a prominent inventor based in Ann Arbor, Michigan, has revolutionized the field of home automation with his ingenious patents. This article explores Kiely's latest patents, career highlights, collaborations, and the significant impact his inventions have had on the industry.

Latest Patents:

John S Kiely's patent portfolio boasts an impressive collection of 58 patents, highlighting his multifaceted expertise in the field. Two of his latest patents, Peptide Nucleic Acid Conjugates and FXR NR1H4 Nuclear Receptor Binding Compounds, stand out as remarkable contributions to the scientific community.

1. Peptide Nucleic Acid Conjugates:

This patent introduces an innovative class of peptide nucleic acids (PNAs) that incorporate ligands, such as naturally occurring DNA bases, attached to a peptide backbone through a suitable linker. The inclusion of ligands enhances the efficacy and versatility of PNAs, enabling potential applications in various fields, including diagnostics, therapeutics, and genetic research.

2. FXR NR1H4 Nuclear Receptor Binding Compounds:

The invention provides compounds that bind to the NRH receptor and function as agonists, antagonists, or mixed agonists/antagonists. These compounds offer promising solutions for treating diseases and conditions through their interaction with the nuclear receptor. The patent also discusses the production of medicaments utilizing these binding compounds, potentially revolutionizing the pharmaceutical industry.

Career Highlights:

Throughout his illustrious career, John S Kiely has demonstrated exceptional dedication and proficiency in the field of innovation and patents. He has worked with prominent companies, contributing significantly to the advancement of technology and scientific research. Notable highlights from his career include his tenures at Warner-Lambert Company and Isis Pharmaceuticals, Inc. (now known as Ionis Pharmaceuticals).

Collaborations:

John S Kiely's creative explorations have not been limited to solo endeavors. He has had the opportunity to collaborate with accomplished professionals, further amplifying the impact of his inventions. Among his respected coworkers, Mel C Schroeder and Sheila H DeWitt are noteworthy, contributing to the success of the projects they worked on together.

Conclusion:

With his extensive patent portfolio and groundbreaking inventions, John S Kiely has solidified his position as a leading innovator in the realm of home automation. By integrating various devices and appliances seamlessly, his smart system offers users an unprecedented level of convenience, comfort, and control over their living spaces. Kiely's patents, career highlights, and collaborations stand as a testament to his unwavering commitment to pushing the boundaries of innovation. As the smart home industry continues to evolve, his contributions will undoubtedly inspire future inventors and shape the future of home automation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…